MDL No. 1658 (SRC)
Welcome to the Merck (Vioxx) Securities Litigation Website
Please be advised that, on June 28, 2016, the Court granted final approval to the Settlement of this Action reached by Lead Plaintiffs, on behalf of themselves and the Settlement Class (defined below), and Defendants. The Stipulation and Agreement of Settlement dated February 8, 2016 can be viewed and downloaded from this website.
The Settlement Class, which is slightly broader than the class previously certified by the Court (see Notice of Pendency of Class Action), consists of:
all persons and entities who, from May 21, 1999 through October 29, 2004, inclusive (the “Settlement Class Period”), purchased or otherwise acquired Merck & Co., Inc. common stock or call options on Merck Common Stock, or sold put options on Merck Common Stock, except for certain persons and entities who are excluded from the Settlement Class by definition as set forth in paragraph 1(bbb) of the Stipulation
Please read the Settlement Notice to fully understand your rights. A copy of the Settlement Notice can be found in the menu at the left of this page.
If you have any questions about the proposed Settlement, or your eligibility to participate in the Settlement, please DO NOT contact any Defendant in the Action or their counsel. Any questions you may have should be directed to the Claims Administrator or Co-Lead Counsel identified on this website.
The claims administration was completed in July 2018. On August 21, 2018, the Motion for Approval of Distribution Plan was filed. On September 13, 2018, the Court entered the Order Approving the Distribution Plan. The first distribution of the net settlement fund occurred in October 2018. The second distribution occurred in January 2020. The third distribution occurred in October 2020. The fourth distribution occurred in June 2021. The fifth distribution occurred in November 2022.